Table 3– Values at baseline and after 12 weeks of high-altitude treatment in patients with and without house dust mite (HDM) sensitisation

	HDM-sensitised patients			Non-HDM-sensitised patients			Significance between groups p-value
	Baseline	12 weeks	p-value	Baseline	12 weeks	p-value	Significance between groups p-value
Subjects n	68			69
ACQ score^#	3.0±1.0	1.6±1.2	<0.001	3.3±1.0	1.8±1.0	<0.001	0.965
AQLQ score^¶	4.0±0.9	5.6±1.0	<0.001	3.8±0.9	5.3±1.1	<0.001	0.952
SNOT-20 score⁺	2.2±0.8	1.5±1.1	<0.001	2.2±0.76	1.6±1.0	<0.001	0.412
Patients on OCS	29 (43)	15 (22)	<0.001	41 (59)	26 (38)	<0.001	0.87
OCS mg·day⁻¹	0 (0–60)	0 (0–40)	<0.001	5.0 (0–110)	0 (0–40)	<0.001	0.668
ICS μg·day⁻¹	1600 (200–8000)	1600 (0–8000)	0.533	1600 (0–8000)	1600 (0–8000)	0.40	0.584
FEV₁ % pred	88.4±20.4	94.2±20.1	0.001	86.5±26.2	92.8±23.1	0.004	0.838
6MWD m	516±178	636±219	<0.001	430±182	575±197	<0.001	0.360
Total IgE kU·L⁻¹	376 (7–5000)	245 (6–4682)	0.003	94 (5–1781)	58 (5–1961)	0.039	0.211
Blood eosinophils per μL of blood	235 (0–1050)	210 (50–570)	0.033	200 (0–880)	200 (0–630)	0.207	0.025
F_eNO ppb	27.6 (5–209)	18.4 (3–70)	<0.001	16 (5–224)	16 (1–61)	0.058	0.033

Data are presented as mean±sd or median (range), unless otherwise stated. Total immunoglobulin (Ig)E and blood eosinophils at 12 weeks were measured in 43 HDM-sensitised and 36 non-HDM-sensitised patients. ACQ: Asthma Control Questionnaire score; AQLQ: Asthma Quality of Life Questionnaire score; SNOT-20: Sino-Nasal Outcome Test; OCS: oral corticosteroids; ICS: inhalation corticosteroids; FEV₁: forced expiratory volume in 1 s; % pred: % predicted; 6MWD: 6-min walking distance; F_eNO: exhaled nitric oxide fraction. ^#: 0–6, where 0=well controlled; ^¶: 1–7, where 7=best quality of life; ⁺: 0–5, where 0=no complaints.